ProMIS Neurosciences receives FDA IND clearance for Alzheimer's antibody PMN310

ProMIS Neurosciences Inc.

FDA cleared IND for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.
Preclinical data showed PMN310's selective binding to toxic oligomers with minimal plaque binding, potentially reducing ARIA risk.
Company plans to initiate Phase 1a trial to evaluate pharmacokinetics, safety, and tolerability in healthy volunteers.
CEO Gail Farfel called the clearance an important corporate milestone toward a next-generation AD therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.